Dosage formulations for acetylcholinesterase inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07939522

ABSTRACT:
Acetylcholinesterase inhibitors are of use for treating a variety of diseases and conditions including Alzheimer's disease. They also affect circadian rhythms. In order to optimize the use of such compounds, the present invention provides dosage forms and methods of treatment wherein an effective amount of a centrally-acting acetylcholinesterase inhibitor is formulated so as to delay its activity for a predetermined period. Suitable acetylcholinesterase inhibitors include galanthamine, lycoramine, analogs thereof and rivastigmine.

REFERENCES:
patent: 4138475 (1979-02-01), McAinsh et al.
patent: 4140756 (1979-02-01), Gallian
patent: 4173626 (1979-11-01), Dempski et al.
patent: 4193985 (1980-03-01), Bechgaard et al.
patent: 4252786 (1981-02-01), Weiss et al.
patent: 4663318 (1987-05-01), Davis
patent: 4900748 (1990-02-01), Brossi et al.
patent: 5051261 (1991-09-01), McGinity et al.
patent: 5055306 (1991-10-01), Barry et al.
patent: 5057317 (1991-10-01), Iida
patent: 5068111 (1991-11-01), Lovrecich et al.
patent: 5091189 (1992-02-01), Heafield et al.
patent: 5151273 (1992-09-01), Korsatko-Wabnegg et al.
patent: 5162117 (1992-11-01), Stupak et al.
patent: 5213811 (1993-05-01), Frisbee et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5376384 (1994-12-01), Eichel et al.
patent: 5407687 (1995-04-01), Coffin et al.
patent: 5427799 (1995-06-01), Valentine et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5462747 (1995-10-01), Radebaugh et al.
patent: 5472708 (1995-12-01), Chen
patent: 5519017 (1996-05-01), Opitz
patent: 5585375 (1996-12-01), Davis
patent: 5589475 (1996-12-01), Snorrason
patent: 5643905 (1997-07-01), Moormann
patent: 5668117 (1997-09-01), Shapiro
patent: 6273260 (2001-08-01), ColDepietro et al.
patent: 6565883 (2003-05-01), Ogorka et al.
patent: 1325632 (1993-12-01), None
patent: 1 326 632 (1994-01-01), None
patent: 1326632 (1994-02-01), None
patent: 2 121 870 (1994-10-01), None
patent: 648771 (1995-04-01), None
patent: 0 653 427 (1995-05-01), None
patent: 653 427 (1995-05-01), None
patent: 879 596 (1998-11-01), None
patent: 88/08708 (1988-11-01), None
patent: WO88/08708 (1988-11-01), None
patent: WO97/03987 (1997-02-01), None
patent: 98/22072 (1998-05-01), None
patent: WO99/21561 (1999-05-01), None
patent: 00/19985 (2000-04-01), None
patent: 00/30446 (2000-06-01), None
patent: 00 38686 (2000-07-01), None
patent: 00/51970 (2000-09-01), None
Conte et al., “Press-Coated Tablets for Time-Programmed Release of Drugs”, Biomaterials, vol. 14, No. 13, pp. 1017-1023.
Nordberg et al. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety, 1998, vol. 19, No. 6, pp. 465-480.
Riemman et al. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Research, 1994, vol. 51, No. 3, pp. 253-267) (Abstract attached).
Faber et al. Am. J. Psychiatry, Jan. 1999, vol. 156, No. 1, p. 156.
Kennedy et al. J. Clin. Invest., 1984, vol. 74, pp. 972-975.
Conte, U, et al. Press-Coated Tablets for Time-Programmed Release of Drugs, Biomaterials. 1993, vol. 14, No. 13 pp. 1017-1023, Entire Document.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, pp. 161-176. Chapter 8 (eds. Joel G. Hardman and Lee E. Limbird, McGraw-Hill, 1996).
Circadian Rhythms and Drug Deliver—Journal of Controlled Release, 16 (1991) 63-74.
Sensitive Liquid Chromatographic Method for Physostigmine in biological fluids using dual-electrode electrochemical Detection—Robin Whelpton & Thomas Moore—Journal of Chromatography 341 (1985) 361-371.
Pub Med—J. Clin Pharamacol, Mar. 29, 1989(3) 278-84—Single dose safety, tolerance and pharmacokinetics of HP 092 in healthy young men: a potential Alzheimer agent—Pur SK, Hsu RS, Ho I, Lassman HB.
Pub Med—J. Clin Pharamacol, Oct. 30, 1990(10) 948-55—Multiple doese pharmacokinetics, safety, and tolerance of velnarine (HP029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disese—Puri SK, Ho I, Hsu R, Lassman HB.
Pub Med—Expert Opin Investig Drugs Apr. 8, 1999(4) 463-71-Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease.—Ringman JM, Cummings, JL.
Pub Med. J. Microencapsul. Feb. 22, 2005(1) 57-66—Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres—Fu X, Ping Q, Gao Y.
Journal of Chromatography 272 (1983) 216-220—Analysis of plasma physostigmine concentrations by liquid chromatography—Robin Whelpton.
Arch Neurol/vol. 58, Mar. 2001—Open-Label, Multicenter, phase 3 extension study of the safety and Efficacy of Donepezil in Patients with Alzheimer Disease—Rachelle S. Doody MD -p. 427-433.
The Effects of Donepezil in Alzheimer's Disease-Results from a Multinational Trial—Derment Geriatr Cogn Disord 1999; 10: 237-244—A. Burns.
International Journal of Chronobiology, vol. 2, 281-289 (1974)—Circadian Variations of Acetylcholinesterase (E.C.3.1.1.7) in Rats Brains 0 H. Schiebeler and H. v. Mayersbach.
Neuroscience Letters 300 (2001) 157-160—Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease—Pia Davidsson.
Brain Research, 122 (1977) 562-267—The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep—Natarajan Sitaram.
JAGS—Jan. 1998—vol. 46, No.—p. 119-120-Aricept-induced nightmares in Alzheimer's Disease.
Tariot P, Gaile SE, Castelli NA, Porsteinsson AP, Treatment of agitation in dementia. New Dir Ment Health Serv 1997; 76: 109-23.
Devanand DP, Behavioral complications and their treatment in Alzheimer's disease, Geriatrics 1997; 52:Suppl 2:S37-39.
Jacobsen FM and Comas-Dias L, Donepezil for psychotropic-induced memory loss, J Clin Psychiatry Oct. 1999;60( 10):698-704.
CummingsJ L, Mendez MF, Alzheimer's disease: cognitive and behavioral pharmacotherapy. Conn Med 1997; 61:543-552.
Cummings JL, Changes in neuropsychiatric symptoms as outcome . . . cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl 4:S1-9.
Cummings JL, Back C, The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6(2Suppl 1):S64-78.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, et al, A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145.
Cummings J, Winblad B, A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007; 7: 1457-63.
Witting W, Kwa IH,Eikelenbloom P, Mirrniran M, Swaab DF, Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry 1990; 7563-72.
Tate B, Aboody-Guterman KS, Morris AM, Walcott EC, Majocha RE, Marotta CA, Disruption of . . . Proc Natl Acad Sci USA 1992;89:7090-4.
Mishirna K, Okawa M, Satoh K, Shimizu T, Hozumi S, Hishikawa Y, Different manifestations of circadian . . . Neurobiol Aging 1997; 18:105-9.
Van Someren EJ, Scherder EJ, Swaab DF, Transcutaneous electrical nerve stimulation (TENS) improves . . . Dis Assoc Disord 1998; 12: 114-8.
Satlin A, Volicer L, Ross V, Herz L, Campbell S, Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992; 149: 1028-32.
Satlin A, Volicer L., Stopa EG, Harper D, Circadian locomotor activity and core-body temperature rhythmsin Alzheimer's disease. Neurobiol Aging 1995; 16:765-71.
Van Someren EJ, Habebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot AM, . . . disease. Biol Psychiatry 1996; 40:259-70.
Saito Y, Yamashita I, Yamazaki K, Okada F, Satorni R, Fujieda T, Circadian fluctuation of . . . brain areas. Life Sci 19

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Dosage formulations for acetylcholinesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dosage formulations for acetylcholinesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage formulations for acetylcholinesterase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2679589

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.